Transcriptome and Metabolome Reveal Accumulation of Key Metabolites with Medicinal Properties of Phylloporia pulla

Summary

Scientists studied a medicinal fungus called Phylloporia pulla to understand which health-promoting compounds it produces and how it makes them. Using advanced genetic and chemical analysis tools, they discovered the fungus produces beneficial compounds like steroids and triterpenoids that have anti-inflammatory and anti-cancer properties, with production peaking around the middle of the fungus’s growth cycle. They identified six key genes that control the production of celastrol, a particularly valuable compound with potential to treat diseases like Alzheimer’s and cancer. This research helps explain why this fungus has been used traditionally in medicine and provides guidance for growing it to maximize production of these beneficial compounds.

Background

Phylloporia pulla is a macrofungal species used in traditional medicine and functional food applications. While the genus Phylloporia has been utilized medicinally, its secondary metabolites remain largely underexplored compared to other medicinal fungi such as Ganoderma and Sanghuangporus species.

Objective

To comprehensively investigate the secondary metabolites of P. pulla and identify regulatory genes involved in their biosynthesis through integrated transcriptome and metabolome analysis. The study aimed to enhance understanding of steroid, steroid derivative, and triterpenoid accumulation during different growth stages.

Results

The genome assembly consisted of 38,086,920 bp with 10,207 protein-coding genes. Transcriptome analysis identified 4,351 differentially expressed genes with steroid biosynthesis pathway significantly enriched. Metabolomic analysis revealed peaks in steroid and triterpenoid accumulation at mid-growth stages (D4-D7). Six key hub genes were identified in the brown module strongly correlated with celastrol biosynthesis, with genes A09829 and A01065 encoding key rate-limiting enzymes FDFT1 and LSS.

Conclusion

This study provides the first multiomics insights into P. pulla’s bioactive secondary metabolites, demonstrating that steroid and triterpenoid accumulation peaks during mid-growth stages when associated genes show elevated expression. The identification of key biosynthetic genes and pathways supports targeted extraction and potential enhancement of medicinal compound production for functional food development.
Scroll to Top